McKibbin, M
Devonport, H
Gale, R
Gavin, M
Lotery, A
Mahmood, S
Patel, P J
Ross, A
Sivaprasad, S
Talks, J
Walters, G
Article History
First Online: 9 July 2015
Competing interests
: Martin McKibbin: Consulting fees from Bayer and Novartis; lecture fees from Bayer, Novartis, Alimera Sciences and Alcon; research funding from Alcon. Helen Devonport: Consulting fees from Bayer; lecture fees from Allergan, Bayer and Novartis. Richard Gale: Consulting fees from Novartis, Bayer, Alimera Sciences; lecture fees from Novartis and Bayer; research funding from Bayer and Fight for Sight. Mike Gavin: Consulting fees from Novartis, Bayer and Alimera Sciences; lecture fees from Bayer and Novartis. Andrew Lotery: Consulting fees from Novartis; lecture fees from Novartis and Bayer; educational grants from Novartis and Bayer; research funding from Novartis. Sajjad Mahmood: Consulting fees from Novartis and Bayer; lecture fees from Novartis and Bayer. Praveen J. Patel: Consulting fees from Bayer and Roche; lecture fees from Allergan; research funding from Bayer. Adam Ross: Consulting fees from Allergan and Bayer; lecture fees from Novartis. Sobha Sivaprasad: Consulting fees from Allergan, Bayer, Novartis and Roche; lecture fees from Allergan, Bayer and Novartis; and research funding from Allergan, Howard, MDS+Bayer, FFS and NIHR+Bayer. James Talks: Consulting fees from Bayer and Novartis; lecture fees from Allergan and Bayer; research funding from Novartis and Bayer. Gavin Walters: Consulting fees from Bayer; lecture fees from Bayer; research funding from Novartis, Bayer, Allergan and Alcon.